EP0584250A1 - Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers - Google Patents

Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Info

Publication number
EP0584250A1
EP0584250A1 EP92912707A EP92912707A EP0584250A1 EP 0584250 A1 EP0584250 A1 EP 0584250A1 EP 92912707 A EP92912707 A EP 92912707A EP 92912707 A EP92912707 A EP 92912707A EP 0584250 A1 EP0584250 A1 EP 0584250A1
Authority
EP
European Patent Office
Prior art keywords
tetrazol
biphenyl
imidazole
methyl
propyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP92912707A
Other languages
German (de)
French (fr)
Other versions
EP0584250A4 (en
Inventor
Pancras Chor Bun Wong
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
EIDP Inc
Original Assignee
EI Du Pont de Nemours and Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by EI Du Pont de Nemours and Co filed Critical EI Du Pont de Nemours and Co
Publication of EP0584250A1 publication Critical patent/EP0584250A1/en
Publication of EP0584250A4 publication Critical patent/EP0584250A4/xx
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids

Definitions

  • This invention relates to novel pharmaceutical compositions containing an angiotensin-II receptor antagonist from a selected class in combination with a calcium channel blocker from a selected class useful for the treatment of hypertension and for the treatment of congestive heart failure.
  • the selected class of angiotensin-II receptor antagonists and the selected class of calcium channel blockers essential as component parts of the novel compositions of this invention are compounds already known in the art as antihypertensive agents.
  • Angiotensin-II receptor antagonists useful in compositions of the invention are included in those compounds disclosed in published European Published application 0 324 377 the disclosure of which is
  • Calcium channel blockers useful in the compositions of this invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine,
  • verapamil verapamil, gallopamil and tiapamil.
  • compositions of this invention contain a calcium channel blocker of the group defined above in combination with an angiotensin-II receptor antagonist compound of the following formula:
  • R 1 is CO 2 H; NHSO 2 CF 3 and
  • R 2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;
  • R 3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon
  • R 4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
  • R 5 is -(CH 2 ) m OR 7 ; -
  • R 6 is H, alkyl of 1 to 5 carbon atoms or OR 10 ;
  • R 7 is H or alkyl of 1 to 4 carbon atoms
  • R 8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
  • R 9 is CF 3 , alkyl of 1 to 6 carbon atoms or phenyl
  • R 10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of
  • n 1 to 5 or a pharmaceutically acceptable salt thereof.
  • Preferred compounds of the above formula are those in which R 1 is
  • R 2 is H.
  • Illustrative compounds of this preferred scope are:
  • the potential antihypertensive effects of the combination of compounds of this invention may be demonstrated by administering the combination of active compounds to conscious spontaneously hypertensive rats. Rats received either orally or intravenously a dose of 0.1-30 mg/kg of the desired calcium channel blocker, or a dose of 0.1-30 mg/kg of the desired angiotensin-II receptor antagonist, or a combination of the two doses of the calcium channel blocker and the angiotensin-II receptor antagonist.
  • Arterial blood pressure is
  • hypertension are also of value in the management of acute and chronic congestive heart failure.
  • These combinations also be expected to be useful in the treatment of secondary hyperaldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and secondary pulmonary hypertension, renal failure such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, end stage renal disease, renal transplant therapy, and the like, renal vascular hypertension, left ventricular dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, luminal hyperplasia, and to minimize the atherosclerotic process.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment.
  • administration can be any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-
  • parenteral i.e., subcutaneous, intravenous
  • administration can be by the oral route.
  • the combinations of compounds can be administered by any conventional means available for use in
  • an angiotensin-II antagonist and calcium channel blocker can be combined with other therapeutic agents, either as individual therapeutic agents or in a combination with additional therapeutic agents.
  • an angiotensin-II antagonist and calcium channel blocker can be combined with other therapeutic agents.
  • antihypertensives and/or diuretics and/or angiotensin converting enzyme inhibitors such as amiloride
  • guanethidene sulfate hydralazine hydrochloride, hydrochlorothiazide, metolazone, metoprolol tartate, methyclothiazide, methyldopa, methyldopate
  • benzthiazide quinethazone, ticrynafan, triamterene, acetazolamide, aminophylline, cyclothiazide, ethacrynic acid, furosemide, merethoxylline procaine, sodium ethacrynate, captopril, delapril hydrochloride,
  • enalapril enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril hydrochloride, ramapril, teprotide, zofenopril calcium, diflusinal and the like.
  • the combinations of active compounds can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard
  • a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
  • compositions of the invention may contain from 10 to 300 mg of the desired calcium channel blocker and 1 to 100 mg of the angiotensin-II receptor antagonist per unit dose one or more times daily.
  • the active ingredients can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs syrups, and suspensions. They can also be administered parenterally, in sterile liquid dosage forms.
  • Gelatin capsules contain the active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
  • Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective
  • Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
  • water a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • saline aqueous dextrose (glucose)
  • glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
  • Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances.
  • suitable stabilizing agents such as sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite, sodium metabisulfite
  • bisulfite, sodium sulfite, or ascorbic acid are suitable stabilizing agents.
  • citric acid and its salts and sodium EDTA are also used.
  • parenteral solutions can contain
  • preservatives such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
  • Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field. Useful pharmaceutical dosage-forms for
  • a large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each as with 100 milligrams of powdered active ingredients, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
  • a mixture of active ingredients in a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a digestible oil such as soybean oil, cottonseed oil
  • the dosage unit is 100 milligrams of active ingredients, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose.
  • Appropriate coatings may be applied to increase the dosage unit.
  • administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
  • An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredients, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Nouvelles compositions pharmaceutiques contenant un antagoniste de l'angiotensine-II combiné à un inhibiteur calcique tel que 2-butyl-4-chloro-1-[2-(1-H-tétrazol-5-yl)biphényl-4-yl) méthyl]-5-(hydroxyméthyl)imidazole et diltiazem, et utilisation de telles compositions pour le traitement de l'hypertension artérielle et de l'insuffisance cardiaque congestive.New pharmaceutical compositions containing an angiotensin-II antagonist combined with a calcium channel blocker such as 2-butyl-4-chloro-1- [2- (1-H-tetrazol-5-yl) biphenyl-4-yl) methyl ] -5- (hydroxymethyl) imidazole and diltiazem, and use of such compositions for the treatment of arterial hypertension and congestive heart failure.

Description

NOVEL COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS Summary of the Invention
This invention relates to novel pharmaceutical compositions containing an angiotensin-II receptor antagonist from a selected class in combination with a calcium channel blocker from a selected class useful for the treatment of hypertension and for the treatment of congestive heart failure.
Background of the Invention
The selected class of angiotensin-II receptor antagonists and the selected class of calcium channel blockers essential as component parts of the novel compositions of this invention are compounds already known in the art as antihypertensive agents.
Angiotensin-II receptor antagonists useful in compositions of the invention are included in those compounds disclosed in published European Published application 0 324 377 the disclosure of which is
incorporated herein by reference.
Calcium channel blockers useful in the compositions of this invention are selected from the group consisting of diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine,
verapamil, gallopamil and tiapamil.
Detailed Description of the Invention The novel compositions of this invention contain a calcium channel blocker of the group defined above in combination with an angiotensin-II receptor antagonist compound of the following formula:
wherein
R1 is CO2H; NHSO2CF3 and
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon
atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
CvF2v+1, where v=1-3; or
R5 is -(CH2)mOR7; -
R6 is H, alkyl of 1 to 5 carbon atoms or OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl;
R10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of
3 to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a pharmaceutically acceptable salt thereof.
Preferred compounds of the above formula are those in which R1 is
and R2 is H. Illustrative compounds of this preferred scope are:
● 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]-5-(hydroxymethyl)imidazole
● 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
SUBSTITUTESHEET ● 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ● 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]imidazole-5-carboxaldehyde
● 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
The potential antihypertensive effects of the combination of compounds of this invention may be demonstrated by administering the combination of active compounds to conscious spontaneously hypertensive rats. Rats received either orally or intravenously a dose of 0.1-30 mg/kg of the desired calcium channel blocker, or a dose of 0.1-30 mg/kg of the desired angiotensin-II receptor antagonist, or a combination of the two doses of the calcium channel blocker and the angiotensin-II receptor antagonist. Arterial blood pressure is
continuously measured directly through a carotid artery catheter and recorded using a pressure transducer and a polygraph. Blood pressure levels after treatment are compared to pretreatment levels.
The combination of active compounds of this
invention are unexpectedly useful in treating
hypertension. They are also of value in the management of acute and chronic congestive heart failure. These combinations also be expected to be useful in the treatment of secondary hyperaldosteronism, primary and secondary pulmonary hyperaldosteronism, primary and secondary pulmonary hypertension, renal failure such as diabetic nephropathy, glomerulonephritis, scleroderma, glomerular sclerosis, proteinuria of primary renal disease, end stage renal disease, renal transplant therapy, and the like, renal vascular hypertension, left ventricular dysfunction, diabetic retinopathy and in the management of vascular disorders such as migraine, Raynaud's disease, luminal hyperplasia, and to minimize the atherosclerotic process.
The combinations of this invention can be
administered for the treatment of hypertension according to the invention by any means that effects contact of the active ingredient compounds with the site of action in the body of a warm-blooded animal in need of such treatment. For example, administration can be
parenteral, i.e., subcutaneous, intravenous,
intramuscular, or intra peritoneal. Alternatively, or concurrently, in some cases administration can be by the oral route.
The combinations of compounds can be administered by any conventional means available for use in
conjunction with pharmaceuticals, either as individual therapeutic agents or in a combination with additional therapeutic agents. For example the combination of this invention of an angiotensin-II antagonist and calcium channel blocker can be combined with other
antihypertensives and/or diuretics and/or angiotensin converting enzyme inhibitors such as amiloride,
atenolol, bendroflumethiazide, chlorothalidone. chlorothiazide, clonidine, cryptenamine acetates and cryptenamine tannates, deserpidine, diazoxide,
guanethidene sulfate, hydralazine hydrochloride, hydrochlorothiazide, metolazone, metoprolol tartate, methyclothiazide, methyldopa, methyldopate
hydrochloride, minoxidil, pargyline hydrochloride, polythiazide, prazosin, propranolol, rauwolfia
serpentina, rescinnamine, reserpine, sodium
nitroprusside, spironolactone, timolol maleate,
trichlormethiazide, trimethophan camsylate,
benzthiazide, quinethazone, ticrynafan, triamterene, acetazolamide, aminophylline, cyclothiazide, ethacrynic acid, furosemide, merethoxylline procaine, sodium ethacrynate, captopril, delapril hydrochloride,
enalapril, enalaprilat, fosinopril sodium, lisinopril, pentopril, quinapril hydrochloride, ramapril, teprotide, zofenopril calcium, diflusinal and the like.
The combinations of active compounds can be administered alone, but are generally administered with a pharmaceutical carrier selected on the basis of the chosen route of administration and standard
pharmaceutical practice.
For the purpose of this disclosure, a warm-blooded animal is a member of the animal kingdom possessed of a homeostatic mechanism and includes mammals and birds.
Pharmaceutical compositions of the invention may contain from 10 to 300 mg of the desired calcium channel blocker and 1 to 100 mg of the angiotensin-II receptor antagonist per unit dose one or more times daily.
The active ingredients can be administered orally in solid dosage forms, such as capsules, tablets, and powders, or in liquid dosage forms, such as elixirs syrups, and suspensions. They can also be administered parenterally, in sterile liquid dosage forms.
Gelatin capsules contain the active ingredients and powdered carriers, such as lactose, starch, cellulose derivatives, magnesium stearate, stearic acid, and the like. Similar diluents can be used to make compressed tablets. Both tablets and capsules can be manufactured as sustained release products to provide for continuous release of medication over a period of hours.
Compressed tablets can be sugar coated or film coated to mask any unpleasant taste and protect the tablet from the atmosphere, or enteric coated for selective
disintegration in the gastrointestinal tract.
Liquid dosage forms for oral administration can contain coloring and flavoring to increase patient acceptance.
In general, water, a suitable oil, saline, aqueous dextrose (glucose), and related sugar solutions and glycols such as propylene glycol or polyethylene glycols are suitable carriers for parenteral solutions.
Solutions for parenteral administration preferably contain a water soluble salt of the active ingredient, suitable stabilizing agents, and if necessary, buffer substances. Antioxidizing agents such as sodium
bisulfite, sodium sulfite, or ascorbic acid, either alone or combined, are suitable stabilizing agents.
Also used are citric acid and its salts and sodium EDTA. In addition, parenteral solutions can contain
preservatives, such as benzalkonium chloride, methyl- or propylparaben, and chlorobutanol.
Suitable pharmaceutical carriers are described in Remington's Pharmaceutical Sciences, A. Osol, a standard reference text in this field. Useful pharmaceutical dosage-forms for
administration of the compounds of this invention can be illustrated as follows: Capsules
A large number of unit capsules are prepared by filling standard two-piece hard gelatin capsules each as with 100 milligrams of powdered active ingredients, 150 milligrams of lactose, 50 milligrams of cellulose, and 6 milligrams magnesium stearate.
Soft Galatin Capsules
A mixture of active ingredients in a digestible oil such as soybean oil, cottonseed oil or olive oil is combinations prepared and injected by means of a
positive displacement pump into gelatin to form soft gelatin capsules containing 100 milligrams of the active ingredients. The capsules are washed and dried. Tablets
A large number of tablets are prepared by
conventional procedures so that the dosage unit is 100 milligrams of active ingredients, 0.2 milligrams of colloidal silicon dioxide, 5 milligrams of magnesium stearate, 275 milligrams of microcrystalline cellulose, 11 milligrams of starch and 98.8 milligrams of lactose. Appropriate coatings may be applied to increase
palatability or delay absorption. Injectable
A parenteral composition suitable for
administration by injection is prepared by stirring 1.5% by weight of active ingredients in 10% by volume propylene glycol. The solution is made to volume with water for injection and sterilized.
Suspension
An aqueous suspension is prepared for oral administration so that each 5 milliliters contain 100 milligrams of finely divided active ingredients, 100 milligrams of sodium carboxymethyl cellulose, 5 milligrams of sodium benzoate, 1.0 grams of sorbitol solution, U.S.P., and 0.025 milliliters of vanillin.

Claims

What is Claimed Is:
1. A pharmaceutical composition comprising a
pharmaceutically acceptable carrier and a therapeutically effective amount of a combination of an angiotensin-II receptor antagonist compound of the formula:
wherein
R1 is CO2H; NHSO2CF3 and
R2 is H, alkyl of 1 to 4 carbon atoms, halogen, or alkoxy of 1 to 4 carbon atoms;
R3 is alkyl, alkenyl or alkynyl of 3 to 7 carbon
atoms;
R4 is H, Cl, Br, I; alkyl of 1 to 4 carbon atoms;
CvF2v+1, where v=1-3; or R5 is
or -COR6;
R6 is H, alkyl of 1 to 5 carbon atoms or OR10;
R7 is H or alkyl of 1 to 4 carbon atoms;
R8 is H, alkyl of 1 to 4 carbon atoms, or acyl of 1 to 4 carbon atoms;
R9 is CF3, alkyl of 1 to 6 carbon atoms or phenyl; R10 is H, alkyl of 1 to 6 carbon atoms, cycloalkyl of
3 to 6 carbon atoms, phenyl or benzyl;
m is 1 to 5 or a pharmaceutically acceptable salt thereof and a calcium channel blocker compound selected from the group consisting of: diltiazem, nifedipine, nitrendipine, nimodipine, niludipine, niguldipine, nicardipine, nisoldipine, amlodipine, felodipine, isradipine, ryosidine, verapamil, gallopamil and tiapamil.
2. The composition of Claim 1 wherein the
angiotensin-II receptor antagonist is selected from the group consisting of:
● 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]-5-(hydroxymethyl)imidazole ● 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ● 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]imidazole-5-carboxaldehyde
● 2-propyl-4-pentafluoroethyl-1-[(2*-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
3. The composition of Claim 2 wherein the calcium
channel blocker is diltiazem.
4. The composition of Claim 3 wherein the
angiotensin-II receptor antagonist is 2-(butyl-4- chloro-1-[2-(1H-tetrazol-5-yl)biphenyl-4- yl)methyl]-5-(hydroxymethyl) imidazole.
5. The composition of Claim 3 wherein the
angiotensin-II receptor antagonist is 2-propyl-4- pentafluoroethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
6. A method of treating hypertension which comprises administering to a patient in need of such treatment a therapeutically effective amount of a composition of Claim 1.
7. The method of Claim 6 wherein the angiotensin-II receptor antagonist is selected from the group consisting of:
● 2-butyl-4-chloro-1-[(2'(1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]-5-(hydroxymethyl)imidazole
● 2-butyl-4-chloro-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-trifluoromethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-chloro-1-[2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxaldehyde ● 2 propyl-4-ethyl-1-[(2'(1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]imidazole-5-carboxylic acid
● 2 propyl-4-ethyl-1-[(2'-1H-tetrazol-5-yl)biphenyl- 4-yl)methyl]imidazole-5-carboxaldehyd
● 2-propyl-4-pentafluoroethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid
● 2-propyl-4-chloro-1-[2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
8. The method of Claim 6 wherein the calcium channel blocker is diltiazem.
9. The method of Claim 8 wherein the angiotensin receptor antagonist is 2-butyl-4-chloro-1-[2-(1H- tetrazol-5-yl)biphenyl-4-yl)methyl]-5- (hydroxymethyl)imidazole.
10. The method of Claim 8 wherein the angiotensin
receptor antagonist is 2-propyl-4- pentafluoroethyl-1-[(2'-(1H-tetrazol-5- yl)biphenyl-4-yl)methyl]imidazole-5-carboxylic acid.
EP92912707A 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers Withdrawn EP0584250A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US70074091A 1991-05-15 1991-05-15
US700740 1991-05-15

Publications (2)

Publication Number Publication Date
EP0584250A1 true EP0584250A1 (en) 1994-03-02
EP0584250A4 EP0584250A4 (en) 1994-03-30

Family

ID=24814683

Family Applications (1)

Application Number Title Priority Date Filing Date
EP92912707A Withdrawn EP0584250A1 (en) 1991-05-15 1992-05-14 Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers

Country Status (11)

Country Link
EP (1) EP0584250A1 (en)
JP (1) JP2930252B2 (en)
AU (1) AU664375B2 (en)
CA (1) CA2103276A1 (en)
CZ (1) CZ281570B6 (en)
IE (1) IE921534A1 (en)
IL (1) IL101858A (en)
MX (1) MX9202243A (en)
NZ (1) NZ242724A (en)
WO (1) WO1992020342A1 (en)
ZA (1) ZA923557B (en)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP3057471B2 (en) 1993-06-07 2000-06-26 武田薬品工業株式会社 Agent for preventing or treating angiotensin II-mediated diseases
JP3883205B2 (en) * 1994-03-29 2007-02-21 メルク エンド カンパニー インコーポレーテッド Treatment of Atherosclerosis with Angiotensin II Receptor Blocking Imidazole
WO1996028185A2 (en) 1995-03-16 1996-09-19 Pfizer Inc. Composition containing amlodipine, or a salt, or felodipine and an ace inhibitor
TR200100062T2 (en) 1998-07-10 2001-06-21 Novartis Ag Anti-hypertensive combination of valsartan and calcium channel blocker
US6204281B1 (en) 1998-07-10 2001-03-20 Novartis Ag Method of treatment and pharmaceutical composition
US7481803B2 (en) * 2000-11-28 2009-01-27 Flowmedica, Inc. Intra-aortic renal drug delivery catheter
US6395728B2 (en) 1999-07-08 2002-05-28 Novartis Ag Method of treatment and pharmaceutical composition
JP4000505B2 (en) 1999-12-01 2007-10-31 第一三共株式会社 Concomitant medications for treating glaucoma
GB0008332D0 (en) * 2000-04-04 2000-05-24 Pfizer Ltd Treament
AU2001267404A1 (en) * 2000-05-04 2001-11-12 Ipf Pharmaceuticals Gmbh Novel compounds for the treatment of inflammatory and cardiovascular diseases
WO2002043807A2 (en) * 2000-12-01 2002-06-06 Novartis Ag Combinations of an angiotensin receptor antagonist and an anti-hypertensive drug or a statin, for the treatment of sexual dysfunction
EG24716A (en) * 2002-05-17 2010-06-07 Novartis Ag Combination of organic compounds
AU2004208615C1 (en) 2003-01-31 2010-05-13 Daiichi Sankyo Company, Limited Medicine for prevention of and treatment for arteriosclerosis and hypertension
TW200833325A (en) * 2006-12-26 2008-08-16 Daiichi Sankyo Co Ltd Pharmaceutical composition comprising ascorbic acid
ES2393885T7 (en) 2007-06-04 2014-01-30 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
ES2522968T3 (en) 2008-06-04 2014-11-19 Synergy Pharmaceuticals Inc. Guanylate cyclase agonists useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
AU2009270833B2 (en) 2008-07-16 2015-02-19 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
CA2905435A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Compositions useful for the treatment of gastrointestinal disorders
JP2016514671A (en) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド Guanylate cyclase agonists and uses thereof
US10011637B2 (en) 2013-06-05 2018-07-03 Synergy Pharmaceuticals, Inc. Ultra-pure agonists of guanylate cyclase C, method of making and using same

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411766A1 (en) * 1989-07-03 1991-02-06 Merck & Co. Inc. Substituted quinazolinones as angiotensin II antagonists
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2607004B1 (en) * 1986-11-20 1990-06-01 Synthelabo PHARMACEUTICAL COMPOSITIONS CONTAINING DILTIAZEM AND AN ANGIOTENSIN CONVERSION ENZYME INHIBITOR
US5015651A (en) * 1988-01-07 1991-05-14 E. I. Du Pont De Nemours And Company Treatment of hypertension with 1,2,4-angiotensin II antagonists

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0411766A1 (en) * 1989-07-03 1991-02-06 Merck & Co. Inc. Substituted quinazolinones as angiotensin II antagonists
WO1992010097A1 (en) * 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
J. PHARMACOL. EXP. THER. (USA), 1990, VOL. 252, NO. 2, PAGE(S) 711-718, Chiu A.T. et al 'Nonpeptide angiotensin II receptor antagonists. VII. Cellular and biochemical pharmacology of DuP 753, an orally active antihypertensive agent' *
See also references of WO9220342A1 *

Also Published As

Publication number Publication date
JPH06508128A (en) 1994-09-14
EP0584250A4 (en) 1994-03-30
CZ281570B6 (en) 1996-11-13
ZA923557B (en) 1993-11-15
AU664375B2 (en) 1995-11-16
NZ242724A (en) 1994-09-27
IL101858A (en) 1996-08-04
IL101858A0 (en) 1992-12-30
CA2103276A1 (en) 1992-11-16
WO1992020342A1 (en) 1992-11-26
IE921534A1 (en) 1992-11-18
MX9202243A (en) 1992-11-01
JP2930252B2 (en) 1999-08-03
AU2026992A (en) 1992-12-30
CZ235193A3 (en) 1994-03-16

Similar Documents

Publication Publication Date Title
EP0584250A1 (en) Novel composition of angiotensin-ii receptor antagonists and calcium channel blockers
EP0565634B1 (en) Angiotensin ii receptor blocking compositions
US5492904A (en) Composition of angiotensin-II receptor antagonists and calcium channel blockers
US5958961A (en) Pharmaceutical composition for angiotensin II-mediated diseases
US4873076A (en) Method of safely providing anesthesia or conscious sedation
EP0533840B1 (en) Treatment of chronic renal failure with imidazole angiotensin-ii receptor antagonists
KR910007927A (en) Condensed imidazole derivatives and preparation methods thereof
EP1306089A1 (en) Combination of benzimidazoles having angiotensin-II antagonistic activity with diuretics or calcium antagonists
HU219404B (en) Process for producing pharmaceutical compositions containing angiotenzin-ii-receptor-blocking compounds for treating cardial and vascular hypertrofie and/or hyperplasy
NZ514058A (en) Medicament for treating hypertension
JP2002537258A5 (en)
GB2270073A (en) Angiotensin II antagonist
JP3057471B2 (en) Agent for preventing or treating angiotensin II-mediated diseases
EP0368972B1 (en) Method of safely providing anesthesia or conscious sedation
JP2008044871A (en) Cardiovascular disease-preventing and treating agent
EP0631780A1 (en) Use of an angiotensin II antagonist as an ocular hypotensive agent
EP0612523B1 (en) Vascular hypertrophy suppressor
KR100222627B1 (en) Novel pharmaceutical composition of angiotensin-ii receptor antagonists and calcium channel blockers
KR101187693B1 (en) Agent for treating or preventing renal disease
CA2459017A1 (en) Medicinal compositions containing angiotensin ii receptor antagonist
GB2227664A (en) Treating hypertension using a thromboxane A2 receptor antagonist
WO2005058326A1 (en) USE OF QUINAZOLINONE DERIVATIVES FOR THE INHIBITION OF TRANSIENT LOWER ESOPHAGEAL SPHINCTER RELAXATIONS (TLESRs)
EP0784976A1 (en) Immunosuppressive-activity potentiating compositions containing ascorbyl tocopheryl phosphoric acid diesters

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19931116

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

A4 Supplementary search report drawn up and despatched

Effective date: 19940208

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IT LI LU MC NL SE

17Q First examination report despatched

Effective date: 19981126

GRAG Despatch of communication of intention to grant

Free format text: ORIGINAL CODE: EPIDOS AGRA

RTI1 Title (correction)

Free format text: COMPOSITION OF ANGIOTENSIN-II RECEPTOR ANTAGONISTS AND CALCIUM CHANNEL BLOCKERS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 20010301